AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00738010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poli-Stim
Description: Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
Study NCT00738010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Voluntary quadriceps muscle contractions.
Study NCT03630718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Intervention
Description: The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient.
Study NCT03630718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis intervention
Description: The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue.
Study NCT01904552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Root Canal Length Measurement Device
Description: Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
Study NCT02354976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Study NCT02223299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deplin
Description: 15mg daily for 30 days
Study NCT02354976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acid
Description: 4 g administered as 4 x 1 g capsules
Study NCT02354976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200mg
Description: 200mg capsule administered once daily
Study NCT02354976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fenofibrate 200mg
Study NCT04690387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
Study NCT02875587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
Study NCT02875587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium gluconate
Description: Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
Study NCT00519480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
Study NCT00519480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
Study NCT00519480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
Study NCT00519480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as an oral tablets.
Study NCT03932565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T therapy for nectin4-positive malignant solid tumor
Description: The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
Study NCT04690387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant
Study NCT02223299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: deplin
Description: 15mg daily for 30 days
Study NCT02223299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: a sugar-pill that looks like a real medication
Study NCT02223299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: a sugar-pill that looks like a real medication
Study NCT01165944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
Study NCT01339078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stenting
Description: The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
Study NCT01339078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kaffes stenting
Description: The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
Study NCT02759627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Gait Training
Description: There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training.
Study NCT04000373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ekso GT™ exoskeleton
Description: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
Study NCT01117714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Staging for Early Detection of Metastases in Lung Cancer
Description: To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
Study NCT02034617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiMoNid
Description: One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
Study NCT04368182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous C-TCR055
Description: Autologous C-TCR055 administered by intravenous (IV) infusion
Study NCT02232269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Coffee
Study NCT02232269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Coffee
Study NCT02232269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Study NCT02232269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT02232269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Study NCT02232269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine
Study NCT02232269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Felodipine
Study NCT04188769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: constant deep pressure applied by an air splint
Description: inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm
Study NCT04188769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent deep pressure applied by an air splint
Description: continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm
Study NCT04188769 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: uninflated air splint
Description: no deep pressure applied by the air splint
Study NCT04188769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: contralateral movement
Description: non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
Study NCT04188769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: contralateral movement
Description: non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
Study NCT04188769 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: contralateral movement
Description: non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
Study NCT02602964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromsucular block
Description: Deep or standard neuromuscular block
Study NCT03996265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride Controlled-release
Description: Given PO
Study NCT03996265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT03996265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03996265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03996265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03996265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02908698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight
Study NCT02908698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
Study NCT03229239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal stroma implantation
Description: During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
Study NCT01496690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
Study NCT01496690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin Placebo Capsules
Description: Parallel to Active Comparator
Study NCT01784419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor
Description: Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
Study NCT01784419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
Study NCT02528422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyl-Ghrelin
Study NCT02528422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyl-Ghrelin
Study NCT03695406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Program for Fear of Recurrence
Description: An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
Study NCT02693652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: * Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection
Study NCT01316588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plastic adesive drape
Description: Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
Study NCT01316588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbial Sealant
Description: Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
Study NCT02736526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recession or resection of the horizontal extraocular muscles
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Canagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
Study NCT01358643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Three home-based diet and exercise programs
Description: All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program.
Study NCT02826759 — intervention group
Intervention type: OTHER
Intervention: diabetes
Description: the exposure of interests are obesity, diabetes and insulin-resistance
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
Study NCT03441737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
Study NCT03441737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Exercise
Description: 20 minutes of sitting in the laboratory with access to magazines and the internet.
Study NCT04913857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24-week SUDOKU Training Programme
Description: 12-week face-to-face training session and a 12-week facilitated self-practice
Study NCT04913857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm (wait-list)
Description: wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
Study NCT00547560 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSI-953
Description: Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
Study NCT03689010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid foam 15%
Description: Azelaic acid foam 15%
Study NCT03689010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea® (Azelaic acid Foam) 15%
Description: Azelaic acid foam 15%
Study NCT03689010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of the test product
Description: Vehicle of the test product
Study NCT03421925 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic totally extraperitoneal procedure for inguinal hernia
Description: Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Description: No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Glucagon-like Peptide-1 (GLP-1) Agonist
Description: No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Anti-hyperglycemic Agents (AHA)
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
Study NCT04635241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Inhaled nebulised 6 hourly
Study NCT05347602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gold Factor (Gold Nanoparticles, AuNPs)
Description: AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
Study NCT05347602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold Factor (Gold Nanoparticles, AuNPs)
Description: AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
Study NCT05347602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.